Crewe Advisors’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Crewe Advisors’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-100	Closed	-$25	–	1190
2026 Q1	$25	Hold	100	–	–	﹤0.01%	1032
2025 Q4	$42	Hold	100	–	–	﹤0.01%	1091
2025 Q3	$68	Hold	100	–	–	﹤0.01%	955
2025 Q2	$55	Hold	100	–	–	﹤0.01%	737
2025 Q1	$66	Buy	+100	New	+$106	﹤0.01%	707

Other funds holding SGMO

AIM

Axiom Investment Management New York $150M AUM

HIG

Heritage Investment Group Pompano Beach, Florida $744M AUM 20.51% 1-Year Est. Return

Crewe Advisors's SGMO Position: Q2 2026 in Review

Crewe Advisors sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2026, closing a stake of 100 shares — an estimated $25 sold.

Crewe Advisors first reported a position in SGMO in Q1 2025 and held it in 5 quarters. The position peaked at $68 in Q3 2025. 2 funds tracked by Wall St. Rank hold SGMO as of Q2 2026.

Crewe Advisors reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2026 after selling out during the quarter.
Crewe Advisors sold 100 SANGAMO THERAPEUTICS INC shares in Q2 2026, an estimated $25.
Crewe Advisors first reported a position in SANGAMO THERAPEUTICS INC in Q1 2025 and held it in 5 quarters.
Crewe Advisors's SANGAMO THERAPEUTICS INC position peaked at $68 in Q3 2025.
2 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2026.

Based on Crewe Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.